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2 These authors contributed equally to this work.Y RNAs are approximately 100 nucleotide long conserved cytoplasmic non-coding RNAs, which pro-
duce smaller RNA fragments during apoptosis. Here we show that these smaller RNA molecules are
also produced in non-stressed cells and in a range of human cancerous and non-cancerous cell
types. Recent reports have speculated that the cleavage products of Y RNAs enter the microRNA
pathway. We tested this hypothesis and found that Y5 and Y3 RNA fragments are Dicer independent,
they are in different complexes than microRNAs and that they are not co-immunoprecipitated with
Ago2. Therefore we conclude that Y RNA fragments do not enter the microRNA pathway.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Y RNAs are a family of non-coding RNAs discovered following
two investigations into the autoimmune disorder systemic lupus
erythematosus (SLE) [1,2], which is characterised by the inﬂamma-
tion of connective tissue. There are four principal Y RNA genes de-
noted Y1, Y3, Y4 and Y5 (Y2 is now considered to be a truncated
form of Y1) [3]. Y RNAs show high evolutionary conservation with-
in the animal kingdom, and there is evidence that orthologs also
exist in prokaryotes [4,5], suggesting that these genes may have
an important function.
All Y RNAs are expressed in human cells [6], although many
other animal species do not contain the full Y RNA complement.
For example, many rodents only possess Y1 and Y3, but both the
mouse and rat genomes have a redundant ‘fossil’ Y5 RNA gene that
is no longer expressed [7]. Y RNA genes are transcribed by RNA
polymerase III into short, 84–113 nt RNAs which fold back on
themselves to form distinct hairpin-containing structures [3].
Although the biological function of Y RNAs is not well understood,
a deﬁning trait of Y RNAs is their ability to bind the 60 kDa protein
Ro60 [2,8,9] and the 47 kDa La protein [8] to form the Ro-RNP
(Ro60 containing ribonucleoprotein complex). These interactions
were shown to inﬂuence the sub-cellular localisation of Ro [10]chemical Societies. Published by E
al Sciences, University of East
ología Molecular (A), Facultad
Spain.and its association with other proteins [11,12]. Y RNAs also bind
to Ro in bacteria, which inhibits other proteins to access Ro [4].
It was found by several groups that the majority of Y RNAs in both
mouse and human cells are bound by Ro [3,13], but a small propor-
tion of Y RNAs is not associated to Ro and this fraction is involved
in the initiation of chromosomal DNA replication [14,15].
The RNA component of Ro-RNPs appears to be altered during
apoptosis. Human Y RNAs are rapidly and speciﬁcally cleaved
during apoptosis in a caspase-dependant manner and this occurs
under the duress of a range of apoptotic stimuli [16]. The degrada-
tion products of the Y RNAs were found to remain bound to Ro60,
and to a lesser extent, the La protein, during the degradation pro-
cess [16]. The Y RNA degradation products were 22–36 nts in size
and were grouped into two classes: a smaller fragment with about
24 nt (22–25 nt) and a larger fragment around 31 nt (27–36 nt)
[16]. The smaller fragments were immunoprecipitated with Ro60
but not with La, while the larger fragments were detected in both
anti-Ro60 and anti-La immunoprecipitation [16].
Another class of small non-coding RNAs is the microRNAs (miR-
NAs) [17]. They are generated by Dicer from precursor-miRNAmol-
ecules that are folded into a hairpin structure, similar to Y RNAs.
MiRNAs are around 22 nt and a recent study has shown that 25 nt
small RNAs derived from hY3 and hY5 RNAs are present in solid
tumour samples at levels comparable with the cancer-associated
miRNA, miRNA-21 [18]. These 25 nt hY3 and hY5 derived RNAs
had been annotated in miRBase as hsa-miR-1979 and hsa-miR-
1975, respectively, but have since been removed as they originate
from Y RNAs. However, it raised the possibility that Y RNAs are pro-
cessed by Dicer and that the smaller Y RNA fragments are actuallylsevier B.V. All rights reserved.
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smaller Y RNAproducts via luciferase assay, but no silencing activity
was observed [18], althoughmiRNA function could not be ruled out
based on that, as discussed in a recent review [19].
In this work, we show that the generation of smaller fragments
from Y5 RNA are not dependant on Dicer, and that these Y5-
derived small RNAs (Y5 sRNAs) are not found in the Ago2 RISC com-
plex. In addition, RNP complexes containing miRNAs and Y5 sRNAs
were in separate fractions following biochemical puriﬁcation, we
therefore conclude that the Y RNA fragments are not miRNAs.
2. Materials and methods
2.1. Cell lines and cell culture
MCF-10A cells were purchased from the American Type Culture
Collection (ATCC) and were cultured in MEGM Bulletkit medium
(Lonza, cc-3150) supplemented with 100 ng/ml cholera toxin
(Sigma, C8052). DLD-1 wild type and DLD-1 dicer/ were pur-
chased from Horizon Discovery. Both the DLD-1 cell lines, and
HCT 116 were cultured in DMEM/F-12 + Glutamax (Gibco, 31331),
supplemented with 10% FBS and 1% penicillin–streptomycin.
2.2. Poly(I:C) treatment
Polyinosinic:polycytidylic acid potassium salt (PolyI:C) (Sigma,
P9582) was used by transfecting into cells at 10 lg/ml in puriﬁed
water. Poly(I:C) transfection media was removed from cells after
5 h of incubation and replaced with fresh media. Cells were
harvested for RNA/protein extraction 3 h after this media change.
2.3. Northern blotting
Total cellular RNA was extracted from cells using Trizol reagent
(Invitrogen, 15596) according to the manufacturer’s instructions.
For Northern analysis was carried out as previously described
[20]. Antisense DNA oligonucleotide probe sequences used were:
Y5 30 end (50-AGCTAGTCAAGCGCGGTTGTGGGGG-30), Y3 (50-TAG-
TCAAGTGAAGCAGTGGGAG-30), miR-21 (50-TCAACATCAGTCTGA-
TAAGCTA-30), U6 snRNA (50-GCTAATCTTCTCTGTATCGTTCC-30).
2.4. Anion chromatography
Native extracts of MCF7 cells were prepared at 24 h after
poly(I:C) induction in extraction buffer (20 mM Tris/HCl pH 7.5,
300 mM NaCl, 5 mM MgCl2, 5 mM DTT freshly added). Insoluble
material was removed by centrifugation for 10 min at 16000 g at
4 C, and the supernatant was ﬁltered through a 0.22 lm syringe
ﬁlter. The extracts were separated using a DEAE-anion exchange
column (Pharmacia, http://www4.gelifesciences.com). Fractions
from the anion exchange column were eluted in different salt
concentration, which was increased as depicted in Fig. 4. RNA
was extracted from every second fraction and analysed on a gel
blot.
2.5. Ago2 pull-down assay
Cells were lysed using Lysis Buffer (Promega, E3971) plus
2.5 mg/ml of heparin (Sigma), spun down and the supernatant
was incubated with 10 ll of Ago2 primary antibody (Abcam,
ab57113) for 4 h at 4 C. Protein A beads were blocked with hepa-
rin and then incubated with the lysate 1 h at 4 C. After four
washes the beads were eluted three times with 100 ll of glycin/
HCl pH 2.3 100 mM. These three elutions were pooled and neutral-
ized with 75 ll of Tris/HCl pH 9.0 (1 M).3. Results
3.1. Y5 RNA cleavage occurs in a range of cancerous and non-
cancerous cell types under stress induced and non-induced conditions
In order to investigate whether Y5 RNA cleavage is unique to
speciﬁc cell types, we selected a range of cell lines and treated
them with the double-stranded RNA mimic immunostimulant
chemical, poly(I:C). Fig. 1A shows that the longer and shorter Y5
sRNAs are produced upon poly(I:C) treatment in both cancerous
cell lines MCF 7 (mammary adenocarcinoma cells), HeLa (cervical
cancer cells), DLD-1 (epithelial adenocarcinoma cells) and HCT
116 (colorectal carcinoma cells) and the non-cancerous HEK 293
(human embryonic kidney cells) and MCF 10A (mammary epithe-
lial cells) cell lines, although the smaller fragments were produced
at a much higher level in MCF7 than in any other cells. The levels of
the longer Y5 sRNA is signiﬁcantly greater in all cells types than the
shorter product as found previously [16].
Owing to the short exposure time that is sufﬁcient to detect Y5
RNA and its cleavage products on a phosphorimager screen after
poly(I:C) treatment, we asked whether Y5 cleavage products could
be detectable at signiﬁcant levels in non-stressed cells. Using a
synthetic RNA oligonucleotide corresponding to the longer Y5
sRNA, we made a dilution series and quantiﬁed the level of Y5
sRNA in MCF 7 cells by Northern analysis in the absence of
poly(I:C) (Fig. 1B). We calculated that the level of the longer Y5
sRNA in the absence of poly(I:C) was approximately 0.27 femtomo-
les per lg of total RNA. To determine whether this level is similar
to other short non-coding RNAs, we carried out similar experi-
ments for miRNAs and found that the level of miRNA-25 (0.34 fem-
tomoles per lg of total RNA) and miRNA-93 (1.4 femtomoles per
lg of total RNA) was similar to the longer Y5 sRNA.
3.2. Processing of Y5 sRNAs is Dicer independent
Having demonstrated that Y5 sRNAs are present in human cells
under normal conditions, we wanted to investigate the biogenesis
of these molecules. As recent work on Y RNAs has hypothesised
that these small RNAs may be microRNAs [18,19], we analysed
the accumulation of Y5 sRNAs in the presence and absence of
Dicer. Both wild-type DLD-1 and DLD-1 Dicer/ cells were
treated with poly(I:C) and analysed by Northern blot. Fig. 2 shows
that the Y5 sRNAs were present in Dicer/ cells following
poly(I:C) treatment, and in fact were produced at a higher level
to that found in DLD-1 parental cells, which was reproducible in
several experiments. The full length Y5 RNA is at a lower level in
the Dicer/ cells and there were a higher rate of cell death (data
not shown), which is also suggested by the lower level of U6 RNA.
One possible explanation for these observations is that Dicer may
process some of the transfected poly(I:C), since it is a dsRNA mimic
and Dicer processes dsRNA. Therefore in the absence of Dicer the
concentration of intact poly(I:C) could be higher leading to a
stronger effect.
3.3. Y5 sRNAs are not in complex with Argonaute 2
After establishing that Y5 sRNAs were not Dicer dependent and
were therefore not involved in the canonical miRNA pathway, we
considered whether they might be loaded directly into the RNA-
induced silencing complex (RISC) in a Dicer-independent fashion.
Therefore, we immunoprecipitated Argonaute 2 (Ago2), a key com-
ponent of the miRISC complex (Fig. 3). The complete lysate from
MCF 7 cells shows that the longer and shorter Y5 sRNAs were pres-
ent following poly(I:C) treatment, but not in untreated cells and
that a miRNA, miR-21, was present under both conditions. Ago2
Fig. 1. Detection and quantiﬁcation of Y5 sRNAs. (A) Northern blotting using an antisense Y5 30 end probe shows that multiple cell lines produce Y5 sRNA fragments during
poly(I:C) treatment. The cancerous cell lines MCF 7, HeLa, DLD-1 and HCT 116 and non-cancerous HEK 293 and MCF 10A all produced sRNA fragments. The membranes were
stripped and re-probed with a U6 speciﬁc probe. (B) Y5 sRNA accumulation level in untreated MCF 7 cells was compared to a dilution series of DNA oligonucleotide with the
sequence of the last 31 nucleotide of Y5 RNA. The experiment was carried out twice and the longer Y5 sRNA was found to have an average cellular concentration of 0.27
femtomoles/lg total RNA. This is comparable to micro RNA levels in the cell such as miRNA-25 and miRNA-93.
Fig. 2. Y3 and Y5 sRNAs are generated in the absence of Dicer. DLD-1 parental and DLD-1 Dicer/ cells were treated with poly(I:C) and 1 lg of total RNA was analysed by
Northern blot using an antisense Y5 or Y3 30 end probe. The Dicer/ genotype was conﬁrmed by stripping and re-probing the membrane with a miR-21 speciﬁc probe.
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resulted in miR-21 being pulled-down in both instances. However,
neither classes of Y5 sRNAs were pulled down via Ago2 immuno-
precipitation under either condition.3.4. miRNAs and Y5 sRNAs are in different complexes
Finally, we tested whether the Y5 sRNAs and miRNAs are co-
puriﬁed biochemically. Protein lysates of poly(I:C) treated cells
Fig. 3. Y3 and Y5 sRNAs are not part of the Ago2 complex. Northern blot analysis
shows that neither the Y5 or Y3 sRNAs were immunoprecipitated by Ago2 in either
the presence or absence of poly(I:C). As a positive control, miR-21 was pulled-down
by Ago2 antibodies.
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the fractions. Northern blot analysis of the fractions revealed that
miRNAs and Y5 sRNAs are in completely different fractions
(Fig. 4). Together, with the Dicer/ mutant and Ago2 pull down
experiments, these data demonstrate that Y5 sRNAs are not
miRNAs.
3.5. Y3 sRNAs are not miRNAs
In addition to Y5 sRNAs, Meiri et al. [18] found miRNA size frag-
ments derived from Y3 RNAs in their small RNA libraries. Since the
sub-cellular localisation of Y5 is more nuclear than other Y RNAs
[21] and it binds some proteins that do not associate with the other
Y RNAs [11,22] we extended our analysis to Y3 sRNAs to investi-
gate whether Y3 sRNAs are miRNAs. Fig. 2 shows that Y3 sRNAs
accumulate in poly(I:C) induced DLD-1 cells at a much lower level
than Y5 sRNAs but nevertheless the level is of Y3 sRNAs is not af-
fected by the mutation in Dicer. Fig. 3 shows that similarly to Y5
sRNAs, Y3 sRNAs do not bind Ago2. Finally we found the Y3 sRNAsFig. 4. Y sRNAs and miRNAs are in different complexes. Protein lysates of poly(I:C) treate
were eluted with increasing salt concentration between 100 and 800 mM as shown abov
analysed by Northern blot using a Y5 30 end (top panel), Y3 30 end (middle panel) or min the same fractions as the smaller Y5 sRNAs after anion exchange
chromatography puriﬁcation of poly(I:C) treated MCF7 cell lysates,
which were different from the fractions where miR-21 was de-
tected. Based on these results we concluded that Y3 sRNA do not
enter the miRNA pathway.
4. Discussion
Canonical miRNAs are generated by Dicer from precursor-miR-
NAs (pre-miRNAs) with a characteristic stem-loop structure and
the mature miRNAs are incorporated into an Ago2 containing RISC
[17]. Since Y RNAs are folded into a stem-loop structure and their
length is very similar to pre-miRNAs, it is possible that they enter
the miRNA pathway. In fact, Rutjes et al. showed that Y RNAs are
cleaved into two classes of smaller fragments during apoptosis:
one class is around 24 nt and the longer class is around 31 nt [16].
In addition, the smaller Y RNA fragments were found in cDNA
libraries of small RNAs by next-generation sequencing [18,23].
Initially it was not noticed that these derived from Y RNAs and they
were named miR-1975 (from Y5) and miR-1979 (from Y3). MiR-
1975was found at a 3.5-fold higher level in precursor B cells of acute
lymphoblastic leukaemia patients than in normal CD34 + cells [23].
Later Meiri et al. sequenced Y1 derived miRNA-like fragments in
addition to the Y3 and Y5 fragments and noticed that these were
derived from Y RNAs [18]. As a consequence, miR-1975 and
miR1979 were removed from miRBase as they were deemed to be
Y RNA fragments and not miRNAs. However, several non-coding
RNAs enter the miRNA pathway, for instance, some transfer RNAs
(tRNAs) and small nucleolar RNAs (snoRNAs) were shown to pro-
duce miRNAs by Dicer that were incorporated into Ago2 miRISC
[24,25]. Based on these observations it was argued that Y RNA de-
rived small RNAs were potential miRNAs [19].
To clarify whether Y RNA derived small RNAs are bona ﬁdemiR-
NAs we characterised these sRNAs in detail focusing on Y3 and Y5
sRNAs. We found that the generation of Y3 and Y5 sRNAs is Dicer
independent (Fig. 2) and that they are not in complex with Ago2
(Fig. 3). We also showed that miRNAs and Y3/5 sRNAs are in differ-
ent complexes (Fig. 4). In line with our results, no silencing activity
was observed for Y RNA derived small RNAs in luciferase assays
[18]. Also, a survey of RNA polymerase III transcripts did not ﬁnd
miRNAs with the exception of miR-886 and the Y RNA derivedd MCF7 cells were separated by anion exchange afﬁnity chromatography. Fractions
e the top panel. RNA was extracted from every second (odd numbers) fractions and
iR-21 (bottom panel) speciﬁc probe.
1230 F.E. Nicolas et al. / FEBS Letters 586 (2012) 1226–1230miR-1975 and miR-1979 [26], suggesting that these are not miR-
NAs. All these results point to the conclusion that Y RNA derived
small RNAs are not miRNAs since we showed that their biogenesis
is different and they do not regulate gene expression through Ago2
association and others showed that they were transcribed by RNA
polymerase III.
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